Your session is about to expire
← Back to Search
Senolytic
Fisetin for Sepsis
Phase 2
Recruiting
Led By Michael Puskarich, MD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights
Study Summary
This trial will test if a drug called fisetin helps reduce the risk of sepsis in older people.
Who is the study for?
The STOP-Sepsis trial is for people aged 65 or older who are hospitalized with a primary diagnosis of acute infection and expected to stay at least 48 hours. They must have a certain level of organ dysfunction but not severe kidney failure, very low blood counts, invasive fungal infections, or be in intensive care.Check my eligibility
What is being tested?
This study tests different doses of Fisetin against a placebo to see if they can reduce the severity of sepsis in older patients by targeting aging cells. It's set up so that more successful treatments get tested on more patients as the trial goes on.See study design
What are the potential side effects?
Potential side effects aren't specified here, but generally could include allergic reactions to Fisetin, possible interactions with other medications being taken, and typical drug-related risks like nausea or headaches.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Difference in the composite cardiovascular, respiratory, and renal sequential organ failure assessment (CRR-SOFA)
Secondary outcome measures
All-cause mortality
Days in the ICU
Organ failure free days
+7 moreTrial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Fisetin- dose 2Experimental Treatment1 Intervention
Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the 2nd does of fisetin.
Group II: Fisetin- dose 1Experimental Treatment1 Intervention
Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis, will be given the first dose of fisetin.
Group III: PlaceboPlacebo Group1 Intervention
Elderly (>=65 years) patients admitted to the hospital with an acute infection and sequential organ failure assessment score sufficient for a diagnosis of sepsis will receive placebo treatment.
Find a Location
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,381 Previous Clinical Trials
1,588,755 Total Patients Enrolled
3 Trials studying Sepsis
1,023 Patients Enrolled for Sepsis
Michael Puskarich, MDPrincipal InvestigatorUniversity of Minnesota
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with HIV, Hepatitis B, or Hepatitis C.My kidney function is severely reduced.I do not have uncontrolled fluid buildup as judged by my doctor.I am currently on life support treatments like dialysis or a ventilator.I am receiving palliative care focused on comfort.I have been admitted to the ICU.I have been admitted to the hospital.I am currently on medication that may interact with other drugs.I have a new or active cancer, not including non-melanoma skin cancers.I am 65 years old or older.I have been diagnosed with an acute infection.
Research Study Groups:
This trial has the following groups:- Group 1: Fisetin- dose 1
- Group 2: Fisetin- dose 2
- Group 3: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the maximum participant capacity for this clinical trial?
"That is correct. Clinicaltrials.gov has registered that the trial, initially posted on August 23rd 2023, is currently enrolling patients. 220 people are expected to be recruited from one site for the study's duration."
Answered by AI
Has the Federal Drug Administration authorized Fisetin- dose 1?
"Although there is no evidence as of yet indicating Fisetin- dose 1's efficacy, there are some data points suggesting its safety. As such, it was monitored with a score of 2."
Answered by AI
Has recruitment for this clinical study commenced yet?
"Affirmative. According to the information published on clinicaltrials.gov, this medical trial has been recruiting patients since its initial posting date of August 23rd 2023 and is enrolling 220 participants at a single site."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger